BTIG lowered those of the company price target on Surgical Staar (WAIT) to $39 from $49 and maintains a Buy rating on the shares as part of a broader research note that updates the company's models on Medical Technology names reflecting management commentary, product launch momentum, competitive updates, and macroeconomic factors. For Staar, BTIG has lowered its ICL – Implantable Collamer Lens – growth expectations in FY25 and beyond amid continued macroeconomic weakness in China, assuming a similar high single-digit volume growth rate will carry over into FY25 with some moderate price gains of 1%-2% on top of volume growth, the analyst tells investors in a research note. This is down from the mid-teens volume growth previously assumed under Staar's previous long-term targets set at its Analyst Day, BTIG adds.
Published first TheFly – the ultimate source for real-time market-breaking financial news. Try Now >>
See the top stocks recommended by analysts >>
Read more about STAA: